Table 3.
Multi-variable cox regression models evaluating KRASG12/G13-mutant cell-free DNA (cfDNA) percentage and Royal Marsden Hospital (RMH) score with respect to overall survival (OS)
| Variable | HR | 95% CI | P value |
|---|---|---|---|
| OS, all 121 patients | |||
| KRASG12/G13 cfDNA (<6.2% versus ≥6.2%) | 0.63 | 0.39–1.02 | 0.060 |
| RMH score (0 or 1 versus 2 or 3) | 0.57 | 0.36–0.90 | 0.015 |
| OS, 88 patients with KRASG12/G13 in FFPE | |||
| KRASG12/G13 cfDNA (<4.0% versus ≥4.0%) | 0.64 | 0.39–1.06 | 0.080 |
| RMH score (0 or 1 versus 2 or 3) | 0.68 | 0.42–1.13 | 0.140 |
HR, hazard ratio; CI, confidence interval.